Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection

Pertuzumab, trastuzumab, and hyaluronidase-zzxf injection may cause serious or life-threatening heart problems. Tell your doctor if you have or have ever had heart disease. Your doctor will order tests before and during your treatment to see if your heart is working well enough for you to safely receive pertuzumab, trastuzumab, and hyaluronidase-zzxf injection. Tell your doctor and pharmacist if you are being treated with anthracycline medications for cancer such as daunorubicin (Cerubidine), doxorubicin (Doxil), epirubicin (Ellence), and idarubicin (Idamycin) at this time or within 7 months after receiving pertuzumab, trastuzumab, and hyaluronidase-zzxf injection. If you experience any of the following symptoms, call your doctor immediately: cough; shortness of breath; swelling of the face, ankles, or lower legs; weight gain (more than 5 pounds [about 2.3 kilograms] in 24 hours); dizziness; loss of consciousness; or fast, irregular, or pounding heartbeat.

Tell your doctor if you are pregnant or plan to become pregnant. Pertuzumab, trastuzumab, and hyaluronidase-zzxf injection may harm your unborn baby. There is a risk that it will cause the baby to be born with birth defects (physical problems that are present at birth). You will need to have a pregnancy test prior to starting treatment and should use birth control to prevent pregnancy during your treatment and for 7 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you become pregnant during your treatment with pertuzumab, trastuzumab, and hyaluronidase-zzxf injection, call your doctor immediately.

Pertuzumab, trastuzumab, and hyaluronidase-zzxf injection may also cause severe lung damage or an allergic reaction. Tell your doctor if you have or have ever had lung disease or if you have a tumor in your lungs, especially if you usually have difficulty breathing at rest. Your doctor will watch you carefully when you receive pertuzumab, trastuzumab, and hyaluronidase-zzxf injection so that your treatment can be interrupted if you experience a serious reaction. If you have any of the following symptoms, tell your doctor immediately: difficulty breathing or shortness of breath.

Keep all appointments with your doctor and the laboratory. Your doctor may order certain tests before and during your treatment to check your body’s response to pertuzumab, trastuzumab, and hyaluronidase-zzxf.

Talk to your doctor about the risks of receiving pertuzumab, trastuzumab, and hyaluronidase-zzxf.

🔔 Why is this medication prescribed?

The combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf is used in combination with chemotherapy to treat certain types of early breast cancer that has spread to nearby tissues. It is also used to treat a certain type of early breast cancer to decrease the chance that a certain type of breast cancer will return. The combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf is also used with docetaxel (Taxotere) to treat certain types of breast cancer that has spread to other parts of the body. Pertuzumab and trastuzumab are in a class of medications called monoclonal antibodies. They work by stopping the growth of cancer cells. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer so that these medications will have a greater effect.

See also  Strontium-89 Chloride

Administrative spending is particularly problematic in United States hospitals, where it makes up about 25% of total hospital spending and accounts for hundreds of billions of dollars in healthcare spending annually, The Commonwealth Fund The percentage of total hospital spending devoted to administration is highest in for-profit hospitals, followed by nonprofit hospitals, teaching hospitals, and finally public hospitals. Outdated reimbursement and reporting methods are a big part of the administrative cost, says Salvo-Wendt. “Reimbursing in bundled payments instead of itemizing each service or component would produce instant savings of administrative costs.”

🔔 How should this medicine be used?

Pertuzumab, trastuzumab, and hyaluronidase-zzxf injection comes as a liquid to be injected subcutaneously (under the skin). Pertuzumab, trastuzumab, and hyaluronidase-zzxf injection is given by a doctor or nurse in a hospital or medical facility. It is usually given into the thigh over 5 to 8 minutes once every 3 weeks. The length of your treatment will depend on the condition that you have and how well your body responds to treatment.

A doctor or nurse will watch you closely while you are receiving the medication and for 15-30 minutes afterwards to be sure you are not having a serious reaction to it. Tell your doctor or nurse immediately if you experience any of the following symptoms: fever; chills; nausea; vomiting; diarrhea; rash; hives; itching; swelling of the face, eyes, mouth, throat, tongue, or lips; difficulty breathing or swallowing; or chest pain.

Your doctor may temporarily or permanently stop your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with pertuzumab, trastuzumab, and hyaluronidase-zzxf.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.